Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2018-09-20 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings
2018-09-20 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement informing stock exchanges about the completion of a USFDA inspection at the company's Bangalore facility. It mentions the issuance of a Form 483 with observations and a recent product approval. The document is brief (1448 characters) and serves as a notification to take the information on record. There is no detailed financial data, no report attached, and no indication of a full report or detailed filing. This fits the profile of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2018-09-18 English
Press Release
Capital/Financing Update Classification · 90% confidence The document is a press release announcing that Strides Pharma Science Limited has received USFDA approval for a specific pharmaceutical product (Potassium Chloride Extended Release Tablets). It is dated September 5, 2018, and is addressed to stock exchanges with scrip codes, indicating a formal announcement to the market. The content focuses on the product approval, market potential, manufacturing details, and company background. There are no financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. The document is relatively short (4422 characters) and serves as a corporate announcement rather than a detailed report. Therefore, it fits best under the category of Capital/Financing Update (CAP) as it relates to a significant business development impacting the company's product portfolio and market presence, which is typical for such updates. It is not an earnings release or regulatory filing, nor is it a report publication announcement or management information. Hence, the most appropriate classification is CAP with high confidence.
2018-09-05 English
Updates
AGM Information Classification · 95% confidence The document is a notice regarding the dispatch of the Notice of the 27th Annual General Meeting (AGM) and Book Closure intimation. It references compliance with SEBI regulations and includes copies of newspaper advertisements confirming the dispatch of AGM notices to shareholders. The document does not contain the AGM materials themselves, nor does it include financial statements or detailed reports. It is an announcement related to the AGM process, specifically the notice and dispatch confirmation, which fits the category of AGM Information (AGM-R). The document length is short and it serves as a communication about the AGM notice dispatch rather than the full AGM report or minutes.
2018-09-04 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the closure of a divestment transaction where a subsidiary ceases to be wholly owned by the company. It is an update on a financing or capital structure event (divestment of a subsidiary). The document is short (1473 characters) and is an announcement of a transaction closure, not a detailed financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP).
2018-08-31 English
AGM/Book Closure
AGM Information Classification · 95% confidence The document is a notice regarding the 27th Annual General Meeting (AGM) of the company, including details about the meeting date, venue, book closure dates, and dividend eligibility cut-off date. It does not contain financial statements or detailed reports but serves as an announcement related to the AGM event. The document length is short (1381 characters), and it is clearly a notice for the AGM rather than the AGM materials or report itself. Therefore, it fits the category of AGM Information (AGM-R).
2018-08-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.